Evacetrapib

Drug Profile

Evacetrapib

Alternative Names: LY-2484595

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics; Benzazepines; Carboxylic acids; Cyclohexanes; Small molecules; Tetrazoles
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipidaemia
  • Phase I Cardiovascular disorders
  • No development reported Atherosclerosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784)
  • 01 Dec 2015 Eli Lilly and Company completes a phase I trial in Dyslipidaemias in USA (NCT02168803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top